ProCE Banner Activity

Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of Relapsed/Refractory Multiple Myeloma

Slideset Download
Download these slides from a live Webinar for up-to-date data on the optimal treatment options for patients with relapsed or refractory myeloma, including treatment algorithms and data on emerging therapies.

Released: March 15, 2021

Expiration: March 14, 2022

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

Janssen administered by Scientific Affairs

Oncopeptides

Program Director Disclosure

Program Director

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Faculty Disclosure

Primary Author

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York